Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence
OPEN BMJ (Clinical research ed.) | 18 Sep 2015
J Le Noury, JM Nardo, D Healy, J Jureidini, M Raven, C Tufanaru and E Abi-Jaoude
To reanalyse SmithKline Beecham’s Study 329 (published by Keller and colleagues in 2001), the primary objective of which was to compare the efficacy and safety of paroxetine and imipramine with placebo in the treatment of adolescents with unipolar major depression. The reanalysis under the restoring invisible and abandoned trials (RIAT) initiative was done to see whether access to and reanalysis of a full dataset from a randomised controlled trial would have clinically relevant implications for evidence based medicine.
* Data courtesy of Altmetric.com